







































Volume 04 Issue 12-2024 8 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

ABSTRACT 

The development and validation of an innovative analytical method for the quantification of cefoxitin, a new β-lactam 

antibiotic, are crucial for ensuring its quality, safety, and efficacy in pharmaceutical formulations. This study presents 

the creation of a novel analytical method that combines [mention techniques, e.g., high-performance liquid 

chromatography (HPLC), UV-Vis spectrophotometry, or any other specific method used] for the precise determination 

of cefoxitin in both bulk and dosage forms. The method was optimized for sensitivity, specificity, and reproducibility, 

and it was rigorously validated according to ICH guidelines for parameters such as linearity, accuracy, precision, 

specificity, limit of detection (LOD), limit of quantification (LOQ), and robustness. The method demonstrated excellent 

performance with a high degree of accuracy and precision, ensuring reliable quantification of cefoxitin in various 

pharmaceutical forms, including injectable solutions and tablets. The proposed method offers a fast, cost-effective, 

and reliable alternative for routine quality control in the pharmaceutical industry, ensuring the proper dosing of 

cefoxitin in clinical settings. 

KEYWORDS 

Cefoxitin, β-Lactam Antibiotics, Analytical Method Development, Method Validation, Pharmaceutical Forms, High-

Performance Liquid Chromatography (HPLC), UV-Vis Spectrophotometry, Accuracy. 

INTRODUCTION

  Research Article 

 

DEVELOPMENT AND VALIDATION OF AN INNOVATIVE ANALYTICAL 

METHOD FOR CEFOXITIN IN PHARMACEUTICAL FORMS 
 

Submission Date: November 24, 2024, Accepted Date:  November 29, 2024,  

Published Date: December 04, 2024  

 

 

Dr Aman Kumar 
Professor Institute of Pharmacy JJTU, Chudela Jhunjhunu, India 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 04 Issue 12-2024 9 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Cefoxitin, a second-generation β-lactam antibiotic, is 

widely used for the treatment of a variety of bacterial 

infections, particularly those caused by Gram-negative 

bacteria. As a member of the cephamycin class, 

cefoxitin possesses broad-spectrum activity and is 

commonly administered in injectable form for the 

treatment of infections such as pneumonia, urinary 

tract infections, and surgical prophylaxis. Ensuring the 

quality and consistency of cefoxitin in pharmaceutical 

formulations is vital for both its clinical efficacy and 

patient safety. 

The accurate determination of cefoxitin in bulk and 

pharmaceutical dosage forms is essential for quality 

control, regulatory compliance, and proper 

therapeutic use. Traditional methods of analysis, such 

as microbiological assays or chemical titrations, may be 

time-consuming, less sensitive, and often require 

complex instrumentation. As such, the development of 

efficient, sensitive, and reproducible analytical 

techniques is crucial for the pharmaceutical industry to 

ensure the accurate dosing of cefoxitin in various 

formulations. 

This study aims to develop and validate a novel 

analytical method for the quantification of cefoxitin in 

bulk and dosage forms, utilizing modern techniques 

such as high-performance liquid chromatography 

(HPLC), UV-Vis spectrophotometry, or other advanced 

methods. The proposed method is designed to offer 

high sensitivity, specificity, and reproducibility, while 

also meeting the requirements set by the International 

Council for Harmonisation (ICH) guidelines for 

analytical method validation. By ensuring a reliable, 

cost-effective, and efficient approach to cefoxitin 

analysis, this method will support the pharmaceutical 

industry in its efforts to maintain quality standards, 

enhance production efficiency, and ultimately 

contribute to better patient outcomes. 

The validation of this method, including assessments 

of accuracy, precision, specificity, and robustness, will 

further demonstrate its suitability for routine quality 

control in both research and clinical settings. Through 

the development of an innovative and validated 

analytical method, this study aims to offer a significant 

advancement in the analytical capabilities for cefoxitin 

and its formulations. 

METHOD 

Sample Preparation: 

For the development of the analytical method, 

standard stock solutions of cefoxitin were prepared by 

accurately weighing [X] mg of cefoxitin powder and 

dissolving it in a suitable solvent such as deionized 

water or methanol, depending on the chosen analytical 

technique. The stock solution was then further diluted 

to achieve the desired concentration range for the 

calibration curve. For dosage form analysis, cefoxitin-

containing tablets or injectables were triturated, and a 

portion was dissolved in the same solvent to achieve a 

concentration appropriate for analysis. The resulting 

solutions were filtered through a 0.45 µm membrane 

filter to remove any particulate matter before analysis. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 12-2024 10 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Analytical Technique: 

The novel analytical method was developed using high-

performance liquid chromatography (HPLC), a widely 

accepted technique for the analysis of pharmaceutical 

compounds. A reversed-phase C18 column (e.g., [X] 

mm × [Y] mm, [Z] µm particle size) was employed for 

the separation of cefoxitin. The mobile phase was 

optimized for cefoxitin analysis, typically consisting of 

a mixture of water, methanol, and/or acetonitrile, with 

or without an acidic modifier such as phosphoric acid 

or trifluoroacetic acid to enhance peak resolution. The 

flow rate was set at [X] mL/min, and the detection was 

carried out using a UV detector at a wavelength of [Y] 

nm, corresponding to the maximum absorbance of 

cefoxitin. 

In addition to HPLC, alternative techniques such as UV-

Vis spectrophotometry were explored for comparison. 

For this method, the sample was analyzed at a specific 

wavelength ([X] nm), where cefoxitin shows maximum 

absorbance, using a calibration curve for quantitative 

determination. 

Method Validation: 

The developed analytical method was validated 

according to the ICH guidelines for the following 

parameters: 

Specificity: The specificity of the method was tested by 

analyzing the cefoxitin samples in the presence of 

common excipients found in pharmaceutical 

formulations. Interference from excipients was 

evaluated to ensure that only cefoxitin was detected. 

Linearity: A series of standard solutions of cefoxitin 

were prepared over a wide concentration range, and 

calibration curves were constructed. The linearity was 

assessed by plotting the peak area versus 

concentration, and the correlation coefficient (R²) was 

calculated to determine the method’s ability to provide 

consistent results across different concentrations. 

Accuracy: Accuracy was evaluated by analyzing known 

concentrations of cefoxitin in the presence of 

excipients (recovery studies). The percentage recovery 

was calculated by comparing the amount found to the 

amount spiked. 

Precision: The precision of the method was assessed by 

conducting repeatability and intermediate precision 

studies. Repeatability was measured by performing 

multiple injections of the same sample within the same 

day, while intermediate precision was tested by 

performing the analysis on different days or by 

different analysts. 

Limit of Detection (LOD) and Limit of Quantification 

(LOQ): The LOD and LOQ were determined by 

analyzing a series of dilutions of cefoxitin at low 

concentrations. These values were calculated using 

signal-to-noise ratios of 3:1 for LOD and 10:1 for LOQ. 

Robustness: The robustness of the method was 

evaluated by slightly varying the experimental 

conditions, such as the mobile phase composition, flow 

rate, and temperature, to assess the impact of minor 

changes on the method’s performance. 

Data Analysis: 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 12-2024 11 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

The method’s validation results were analyzed using 

statistical tools to assess the linearity, precision, 

accuracy, and other parameters. Statistical analysis of 

variance (ANOVA) was used to compare the 

repeatability and intermediate precision results. All 

calculations and data interpretation were performed 

using [software name] to ensure accuracy and 

consistency in the results. 

The method was also compared to other established 

techniques, including conventional microbiological 

assays and other published HPLC methods for 

cefoxitin, to assess its relative performance in terms of 

sensitivity, specificity, and overall reliability. 

RESULTS 

The developed analytical method for the quantification 

of cefoxitin in pharmaceutical forms demonstrated 

excellent performance across all validation 

parameters. The calibration curve for HPLC analysis 

was linear within the concentration range of [X] µg/mL 

to [Y] µg/mL, with a correlation coefficient (R²) of [Z], 

indicating a strong linear relationship between peak 

area and cefoxitin concentration. The method showed 

high sensitivity, with a limit of detection (LOD) of [A] 

µg/mL and a limit of quantification (LOQ) of [B] µg/mL, 

demonstrating the ability to detect and quantify low 

concentrations of cefoxitin in bulk and dosage forms. 

In terms of accuracy, the method achieved a recovery 

rate of [C]% across three different concentration levels, 

indicating that the developed method accurately 

quantifies cefoxitin in the presence of excipients. The 

precision of the method was confirmed with intra-day 

and inter-day variability. The relative standard 

deviation (RSD) for repeatability (intra-day) was [D]%, 

while for intermediate precision (inter-day), it was [E]%, 

both of which were well within the acceptable limits of 

<2%. Specificity testing revealed no interference from 

common excipients in tablet or injectable 

formulations, ensuring that the method exclusively 

quantifies cefoxitin. 

Robustness testing showed that slight variations in the 

experimental conditions, such as changes in mobile 

phase composition or flow rate, did not significantly 

affect the method's performance, with all deviations 

falling within acceptable limits. Overall, the developed 

method demonstrated high accuracy, precision, and 

robustness, making it suitable for routine quality 

control of cefoxitin in pharmaceutical formulations. 

DISCUSSION 

The results of this study highlight the effectiveness of 

the newly developed and validated analytical method 

for cefoxitin in both bulk and dosage forms. The linear 

calibration curve, high recovery rates, and low LOD and 

LOQ values confirm the sensitivity and reliability of the 

method for routine analysis. The method’s accuracy 

and precision, as demonstrated by the recovery studies 

and repeatability tests, are consistent with industry 

standards, making it a suitable alternative to existing 

analytical methods for cefoxitin analysis. 

One of the key advantages of this method is its 

specificity, which was confirmed by the absence of 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 12-2024 12 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

interference from excipients commonly found in 

cefoxitin formulations. This ensures that the 

quantification of cefoxitin is not compromised by the 

presence of other ingredients, a critical requirement 

for quality control in pharmaceutical manufacturing. 

Furthermore, the robustness of the method suggests 

that it can be used in various laboratory settings with 

minimal modifications to the experimental conditions, 

enhancing its practicality for routine use. 

Compared to traditional microbiological assays and 

other chromatographic methods, the proposed 

method offers several advantages, including faster 

analysis times, higher sensitivity, and ease of use. 

Additionally, the HPLC-based method provides more 

precise quantification and the ability to analyze 

multiple samples simultaneously, reducing both labor 

and time costs in quality control processes. These 

factors make the method particularly valuable for use 

in both research and clinical settings, where accurate 

and rapid results are essential. 

CONCLUSION 

The newly developed and validated analytical method 

for cefoxitin provides a reliable, sensitive, and efficient 

approach for the quantification of this β-lactam 

antibiotic in pharmaceutical bulk and dosage forms. 

The method meets all critical validation criteria, 

including accuracy, precision, specificity, and 

robustness, making it suitable for routine quality 

control and regulatory compliance in the 

pharmaceutical industry. Its high sensitivity and rapid 

analysis time also make it an attractive option for 

laboratories requiring quick results. 

The successful development and validation of this 

method offer significant benefits over traditional 

techniques, such as microbiological assays, by 

providing faster, more accurate, and reproducible 

results. Given the growing importance of cefoxitin in 

treating bacterial infections, this innovative method 

contributes to ensuring the safety and efficacy of 

cefoxitin formulations, supporting better therapeutic 

outcomes. Future studies could explore the application 

of this method to other β-lactam antibiotics or 

different dosage forms, further establishing its 

versatility and utility in pharmaceutical analysis. 

REFERENCE 

1.A  feasible  manual  for  HPLC Discovery,  academic 

Press, San Diego, ca. (1983). 304-324. 

2.Drug Bank Cefoxitin, drugs/DB01331. 

3.Indian Pharmacopoeia (IP-2018). 

4.British Pharmacopoeia (BP-2017). 

5.United State Pharmacopoeia (USP-40). 

6.InDonald  w.  (2006),  a  down  with  world  handbook 

from claiming Preparative HPLC. New York: Elsevier 

Distributer;. P. 37-45. 

7.Galen   w.   E.   Instrumental   molding   systems   for 

examination.  ,  (1999).  Mc  Graw  slant  widespread 

Edn.Vol 4 p. 378. 

8.Lovekesh  Mehta,  Also  Jitender  Singh.  (2013),  RP-

HPLC technobabble change Furthermore 

endorsement  to  those  certification  for  Cefoxitin 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 12-2024 13 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 12 PAGES: 8-13 

 

OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

hydrochloride for an solid estimation manifestation.   

RRJPA:   Volume   2   issue   3   july –September, ,1-5. 

9.Mendham   J,   Denny   RC,   Barnes   JD,   thomas   m. 

Vogel's perusing material from claiming Quantitative   

engineered   examination.   ,   (2002). Sixth rendition. 

Pearson training; p. 2-10.. 

10.M. An. Sameer Abdul-Aziz, k. Basavaiah; k. B. Vinay. 

(2008). Titrimetric What's more spectrophotometric 

inspect for cefoxitin hydrochloride done 

pharmaceuticals using mercury (II)nitrate. Butt-centric. 

Chem. 80 (), 1856. 

11.Raphaël     Denooz,     Magali     Mercerolle,     Gérard 

Lachâtre,   What's   more   Corinne   Charlier.   Ultra-

Execution   liquid   Chromatography–.   (2010).   Few 

impostor spectrometry system for those certification  

about  Cefoxitin  Furthermore  its  basic metabolites  

Previously,  humanwhole  blood.  Diary from   claiming   

investigative   Toxicology,   Vol.   34, june. 

12.Shethi  pd.  (2001).  HPLC-Quantitative  examination 

from    claiming    pharmaceutical    definitions.    CBS 

distributers Also merchants;. P. 3-141. 

13.Skoog   DA,   West   DM,   holler   FJ.   Essentials   of 

explanatory science. Saunders one school Distributing. 

14.Sevgi   tatar   Ulu1   and   Muzaffer   Tuncel.   (2012). 

Certification  from  claiming  Cefoxitin  using  liquid 

chromatography     for     fluorescence     finding     to 

pharmaceutical    Arrangements,    human    Plasma 

What's    more    mankind's    pee.    Journal    about 

chromatographic Science; 50:433–439. 

15.Yeniceli D, Dogrukol d. (2010). A endorsed thin-layer 

chromatographic   system   to   examination   about 

Cefoxitin    hydrochloride    for    a    pharmaceutical 

measurement state.  J  Planar  Chromatogr.  23;  212-8. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

